Jean Y. H. Lee

Jean Y. H. Lee

Auto-generated profile, based on publicly available information

Jean Y. H. Lee

Department of Microbiology and Immunology, The University of Melbourne at The Doherty Institute for Infection and Immunity, Victoria, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
BHBenjamin P. Howden
Benjamin P. Howden
SGStefano G. Giulieri
Stefano G. Giulieri
Tania Wong Fok LungTania Wong Fok Lung
Tania Wong Fok Lung
SBSarah L Baines
Sarah L Baines
LSLiam Sharkey
Liam Sharkey
TSTimothy Stinear
Timothy Stinear

3 September 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
JLJean Y. H. Lee
Jean Y. H. Lee
IMIan Monk
Ian Monk
ASAnders Gonçalves da Silva
Anders Gonçalves da Silva
TSTorsten Seemann
Torsten Seemann
KCKyra Y. L. Chua
Kyra Y. L. Chua
BHBenjamin P. Howden
Benjamin P. Howden

1 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
APAcha Pidot
Acha Pidot
WGWei Gao
Wei Gao
ABAndrew H. Buultjens
Andrew H. Buultjens
IMIan Monk
Ian Monk
RGRomain Guerillot
Romain Guerillot
TSTimothy Stinear
Timothy Stinear
The multidrug-resistant bacteriumEnterococcus faeciumhas become increasingly tolerant to the alcohols in hospital disinfectants.

7 May 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
NSNorelle L. Sherry
Norelle L. Sherry
JLJean Y. H. Lee
Jean Y. H. Lee
SGStefano G. Giulieri
Stefano G. Giulieri
CCChristopher H. Connor
Christopher H. Connor
KHKristy Horan
Kristy Horan
BHBenjamin P. Howden
Benjamin P. Howden
Antimicrobial resistance (AMR) is a critical global public health threat, with bacterial pathogens of primary concern. Pathogen genomics has revolutionized the study of bacterial pathogens and provided deep insights into the mechanisms and dissemination of AMR, with the precision of whole-genome sequencing informing better control strategies. However, generating actionable data from genomic surveillance and diagnostic efforts requires integration at the public health and clinical interface that goes beyond academic efforts to identify resistance mechanisms, undertake post hoc analyses of outbreaks, and share data after research publications. In addition to timely genomics data, consideration also needs to be given to epidemiological sampling frames, analysis, and reporting mechanisms that meet International Organization for Standardization (ISO) standards and generation of reports that are interpretable and actionable for public health and clinical “end-users.” Importantly, ensuring all countries have equitable access to data and technology is critical, through timely data sharing following the FAIR principles (findable, accessible, interoperable, and re-usable). In this review, we describe (i) advances in genomic approaches for AMR research and surveillance to understand emergence, evolution, and transmission of AMR and the key requirements to enable this work and (ii) discuss emerging and future applications of genomics at the clinical and public health interface, including barriers to implementation. Harnessing advances in genomics-enhanced AMR research and embedding robust and reproducible workflows within clinical and public health practice promises to maximize the impact of pathogen genomics for AMR globally in the coming decade.

23 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
ATAdrianna M. Turner
Adrianna M. Turner
LLLucy Li
Lucy Li
IMIan Monk
Ian Monk
JLJean Y. H. Lee
Jean Y. H. Lee
DIDanielle J. Ingle
Danielle J. Ingle
GCGlen P. Carter
Glen P. Carter
Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health1. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action2, but for which resistance has been widely reported but is unexplained. Here we show that rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in patients with liver disease3, causes cross-resistance to daptomycin in VREfm. Amino acid changes arising within the bacterial RNA polymerase in response to rifaximin exposure cause upregulation of a previously uncharacterized operon (prdRAB) that leads to cell membrane remodelling and cross-resistance to daptomycin through reduced binding of the antibiotic. VREfm with these mutations are spread globally, making this a major mechanism of resistance. Rifaximin has been considered ‘low risk’ for the development of antibiotic resistance. Our study shows that this assumption is flawed and that widespread rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin, a major last-resort intervention for multidrug-resistant pathogens. These findings demonstrate how unanticipated antibiotic cross-resistance can undermine global strategies designed to preserve the clinical use of critical antibiotics.

1 September 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JLJean Y. H. Lee
Jean Y. H. Lee
NBNickala Best
Nickala Best
JMJulie McAuley
Julie McAuley
JPJessica L. Porter
Jessica L. Porter
TSTorsten Seemann
Torsten Seemann
TSTimothy Stinear
Timothy Stinear
Introduction. The SARS-CoV-2 pandemic of 2020 has resulted in unparalleled requirements for RNA extraction kits and enzymes required for virus detection, leading to global shortages. This has necessitated the exploration of alternative diagnostic options to alleviate supply chain issues. Aim. To establish and validate a reverse transcription loop-mediated isothermal amplification (RT- LAMP) assay for the detection of SARS-CoV-2 from nasopharyngeal swabs. Methodology. We used a commercial RT-LAMP mastermix from OptiGene in combination with a primer set designed to detect the CDC N1 region of the SARS-CoV-2 nucleocapsid (N) gene. A single-tube, single-step fluorescence assay was implemented whereby 1 µl of universal transport medium (UTM) directly from a nasopharyngeal swab could be used as template, bypassing the requirement for RNA purification. Amplification and detection could be conducted in any thermocycler capable of holding 65 °C for 30 min and measure fluorescence in the FAM channel at 1 min intervals. Results. Assay evaluation by assessment of 157 clinical specimens previously screened by E-gene RT-qPCR revealed assay sensitivity and specificity of 87 and 100%, respectively. Results were fast, with an average time-to-positive (Tp) for 93 clinical samples of 14 min (sd±7 min). Using dilutions of SARS-CoV-2 virus spiked into UTM, we also evaluated assay performance against FDA guidelines for implementation of emergency-use diagnostics and established a limit-of-detection of 54 Tissue Culture Infectious Dose 50 per ml (TCID50 ml−1), with satisfactory assay sensitivity and specificity. A comparison of 20 clinical specimens between four laboratories showed excellent interlaboratory concordance; performing equally well on three different, commonly used thermocyclers, pointing to the robustness of the assay. Conclusion. With a simplified workflow, The N1 gene Single Tube Optigene LAMP assay (N1-STOP-LAMP) is a powerful, scalable option for specific and rapid detection of SARS-CoV-2 and an additional resource in the diagnostic armamentarium against COVID-19.